DE1617576C3 - Verfahren zur Herstellung eines Injektionspräparates auf Basis einer wäßrigen Lösung eines Oxytetracyclin-Magnesium-Komplexes - Google Patents
Verfahren zur Herstellung eines Injektionspräparates auf Basis einer wäßrigen Lösung eines Oxytetracyclin-Magnesium-KomplexesInfo
- Publication number
- DE1617576C3 DE1617576C3 DE1617576A DEK0062395A DE1617576C3 DE 1617576 C3 DE1617576 C3 DE 1617576C3 DE 1617576 A DE1617576 A DE 1617576A DE K0062395 A DEK0062395 A DE K0062395A DE 1617576 C3 DE1617576 C3 DE 1617576C3
- Authority
- DE
- Germany
- Prior art keywords
- oxytetracycline
- hours
- polyvinylpyrrolidone
- injection
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000002347 injection Methods 0.000 title claims description 39
- 239000007924 injection Substances 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 20
- 239000011777 magnesium Substances 0.000 title claims description 7
- 229910052749 magnesium Inorganic materials 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 6
- 239000007864 aqueous solution Substances 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 34
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 34
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 34
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 32
- 239000004100 Oxytetracycline Substances 0.000 claims description 31
- 229960000625 oxytetracycline Drugs 0.000 claims description 31
- 235000019366 oxytetracycline Nutrition 0.000 claims description 31
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000002681 magnesium compounds Chemical class 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 56
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 22
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 14
- 239000000395 magnesium oxide Substances 0.000 description 12
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 12
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 12
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 11
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 9
- 230000036765 blood level Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960002337 magnesium chloride Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- IYBQHJMYDGVZRY-UHFFFAOYSA-N lidocaine hydrochloride Chemical compound [Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C IYBQHJMYDGVZRY-UHFFFAOYSA-N 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- -1 magnesium chloride Chemical class 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003924 oxytetracycline dihydrate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL6607516A NL6607516A (enExample) | 1966-05-31 | 1966-05-31 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1617576A1 DE1617576A1 (de) | 1972-04-27 |
| DE1617576B2 DE1617576B2 (de) | 1980-04-10 |
| DE1617576C3 true DE1617576C3 (de) | 1980-12-11 |
Family
ID=19796753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1617576A Expired DE1617576C3 (de) | 1966-05-31 | 1967-05-26 | Verfahren zur Herstellung eines Injektionspräparates auf Basis einer wäßrigen Lösung eines Oxytetracyclin-Magnesium-Komplexes |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3557280A (enExample) |
| JP (1) | JPS5010373B1 (enExample) |
| AT (1) | AT272522B (enExample) |
| BE (1) | BE699091A (enExample) |
| CH (1) | CH490087A (enExample) |
| CS (1) | CS151454B2 (enExample) |
| DE (1) | DE1617576C3 (enExample) |
| DK (1) | DK117587B (enExample) |
| ES (1) | ES340956A1 (enExample) |
| FI (1) | FI43622B (enExample) |
| FR (1) | FR5953M (enExample) |
| GB (1) | GB1131007A (enExample) |
| GR (1) | GR33861B (enExample) |
| IL (1) | IL28009A (enExample) |
| IT (1) | IT1140250B (enExample) |
| LU (1) | LU53788A1 (enExample) |
| MY (1) | MY7100015A (enExample) |
| NL (1) | NL6607516A (enExample) |
| NO (1) | NO126298B (enExample) |
| SE (1) | SE354417B (enExample) |
| SU (1) | SU510986A3 (enExample) |
| YU (1) | YU31326B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5418330B2 (enExample) * | 1973-03-16 | 1979-07-06 | ||
| US3966905A (en) * | 1973-05-29 | 1976-06-29 | Barnes-Hind Pharmaceuticals, Inc. | Stabilized catechol amine solutions |
| US3929989A (en) * | 1974-06-14 | 1975-12-30 | Wendt Lab Inc | Stable suspension of calcium-magnesium oxytetracycline for intrauterine administration in treatment of bovine metritis |
| GB1538903A (en) * | 1975-04-11 | 1979-01-24 | Nelson Res & Dev | Carrier for a topically applied physiologically active agent or cosmetic agent |
| US4018889A (en) * | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| DE2602363C2 (de) * | 1976-01-22 | 1984-04-12 | Bayer Ag, 5090 Leverkusen | Wäßrige, injizierbare Niclofolan- Formulierungen |
| GB1592053A (en) * | 1976-12-16 | 1981-07-01 | Norbrook Lab Ltd | Oxytetracycline compositions |
| US4213963A (en) * | 1978-12-14 | 1980-07-22 | Janssen Pharmaceutica N.V. | Fluspirilene-containing compositions |
| US4259331A (en) * | 1979-04-16 | 1981-03-31 | Pfizer Inc. | Oxytetracycline compositions |
| US4386083A (en) * | 1980-04-10 | 1983-05-31 | Walter Hacke | Injectable oxytetracycline compositions |
| US4399127A (en) * | 1980-04-10 | 1983-08-16 | Diamond Shamrock Corporation | Injectable oxytetracycline compositions |
| IE74244B1 (en) * | 1985-10-01 | 1997-07-16 | Bimeda Res Dev Ltd | A process for preparing an antibiotic composition |
| US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
| US6756365B2 (en) * | 1991-11-06 | 2004-06-29 | Trustees Of Tufts College | Reducing tetracycline resistance in living cells |
| EP0626171A1 (de) * | 1993-05-26 | 1994-11-30 | Winfried Dörnhöfer | Injektionslösung für die intravenöse oder intramuskuläre Verabreichung an Tiere |
| US6383515B2 (en) | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
| US8106225B2 (en) * | 1999-09-14 | 2012-01-31 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| US6500812B2 (en) | 1999-09-14 | 2002-12-31 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| HRP20020322B1 (en) | 1999-09-14 | 2009-04-30 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| US6849615B2 (en) | 1999-09-14 | 2005-02-01 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| WO2001052858A1 (en) * | 2000-01-24 | 2001-07-26 | Trustees Of Tufts College | Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| EP1272459B1 (en) | 2000-03-31 | 2007-06-27 | Trustees Of Tufts College | 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| EP2308863A1 (en) * | 2000-05-15 | 2011-04-13 | Paratek Pharmaceuticals, Inc. | 7-substituted fused ring tetracycline compounds |
| US20020132798A1 (en) * | 2000-06-16 | 2002-09-19 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
| AU2001268475A1 (en) * | 2000-06-16 | 2002-01-02 | Trustees Of Tufts College | 7-phenyl-substituted tetracycline compounds |
| US20040224927A1 (en) * | 2000-06-16 | 2004-11-11 | Trustees Of Tufts College | 7-N-substituted phenyl tetracycline compounds |
| KR101083571B1 (ko) | 2000-07-07 | 2011-11-14 | 파라테크 파마슈티컬스, 인크. | 7-치환 테트라사이클린 화합물 |
| IL153674A0 (en) | 2000-07-07 | 2003-07-06 | Tufts College | 13-substituted methacycline compounds |
| US20050143353A1 (en) * | 2000-07-07 | 2005-06-30 | Paratek Pharmaceuticals, Inc. | 13-Substituted methacycline compounds |
| EP1303479B1 (en) | 2000-07-07 | 2011-04-06 | Trustees Of Tufts College | 7-, 8- and 9-substituted tetracycline compounds |
| ATE544745T1 (de) | 2000-07-07 | 2012-02-15 | Tufts College | 9-substituierte minocyclinverbindungen |
| US7094806B2 (en) | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| AU2002250331A1 (en) * | 2001-03-13 | 2002-09-24 | Paratek Pharmaceuticals, Inc. | 7-pyrollyl tetracycline compounds and methods of use thereof |
| ATE404528T1 (de) | 2001-03-13 | 2008-08-15 | Paratek Pharm Innc | 7,9 substituierte tetracyclinverbindungen |
| CA2457234A1 (en) * | 2001-03-14 | 2002-09-19 | Mark L. Nelson | Substituted tetracycline compounds as antifungal agents |
| JP2005504722A (ja) | 2001-03-14 | 2005-02-17 | パラテック ファーマシューティカルズ インコーポレイテッド | 相乗的抗真菌薬剤としての置換テトラサイクリン化合物 |
| US8088820B2 (en) * | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| ATE455092T1 (de) | 2001-04-24 | 2010-01-15 | Paratek Pharm Innc | Substituierte tetracyclin-verbindungen zur behandlung von malaria |
| ES2551708T3 (es) | 2002-01-08 | 2015-11-23 | Paratek Pharmaceuticals, Inc. | Compuestos de 4-desdimetilamino tetraciclina |
| EP2301534A1 (en) | 2002-03-08 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | Amino-methyl substituted tetracycline compounds |
| CN1653037A (zh) | 2002-03-21 | 2005-08-10 | 帕拉特克药品公司 | 取代的四环素化合物 |
| AU2003261161B2 (en) | 2002-07-12 | 2009-09-10 | Paratek Pharmaceuticals, Inc | 3, 10, and 12a substituted tetracycline compounds |
| AU2003287218C1 (en) | 2002-10-24 | 2010-07-15 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| EP1605916A4 (en) * | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE |
| EP1648859B1 (en) | 2003-07-09 | 2013-02-27 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| US20060287283A1 (en) * | 2003-07-09 | 2006-12-21 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| US20050137174A1 (en) | 2003-07-09 | 2005-06-23 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| CA2553510C (en) * | 2004-01-15 | 2012-09-25 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
| TWI261038B (en) * | 2004-08-11 | 2006-09-01 | Bo-Cheng Chen | Bicycle gear-shifting handgrip |
| US8466132B2 (en) | 2004-10-25 | 2013-06-18 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| US7858601B2 (en) * | 2004-10-25 | 2010-12-28 | Paratek Pharmaceuticals, Inc. | 4-substituted tetracyclines and methods of use thereof |
| JP2008530023A (ja) | 2005-02-04 | 2008-08-07 | パラテック ファーマシューティカルズ インコーポレイテッド | テトラサイクリン化合物の１１ａ，１２−誘導体 |
| DE102005012595A1 (de) * | 2005-03-18 | 2006-09-21 | Lanxess Deutschland Gmbh | Herstellung von Tri(chlorpropyl)phosphat |
| US20070093455A1 (en) * | 2005-07-21 | 2007-04-26 | Paul Abato | 10-substituted tetracyclines and methods of use thereof |
| WO2007035448A2 (en) * | 2005-09-19 | 2007-03-29 | Albemarle Corporation | Highly concentrated pourable aqueous solutions of potassium ibuprofen their preparation and their uses |
| EP2298324A1 (en) | 2006-01-24 | 2011-03-23 | Paratek Pharmaceuticals, Inc. | Methods of increasing oral bioavailability of tetracyclines |
| EP2007713A2 (en) * | 2006-04-17 | 2008-12-31 | Teva Pharmaceutical Industries Ltd | Isolation of tetracycline derivatives |
| PL2016045T3 (pl) * | 2006-04-24 | 2015-04-30 | Teva Pharma | Krystaliczna postać tygecykliny i sposoby jej otrzymywania |
| US8198470B2 (en) * | 2006-04-24 | 2012-06-12 | Teva Pharmaceutical Industries Ltd. | Crystalline form II of tigecycline and processes for preparation thereof |
| EP2537934A3 (en) * | 2006-05-15 | 2013-04-10 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| US8440646B1 (en) | 2006-10-11 | 2013-05-14 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of Bacillus anthracis infections |
| SI2120963T1 (sl) | 2006-12-21 | 2019-02-28 | Paratek Pharmaceuticals, Inc. | Substituirane spojine tetraciklina za zdravljenje vnetnih kožnih motenj |
| JP5583411B2 (ja) | 2006-12-21 | 2014-09-03 | パラテック ファーマシューティカルズ インコーポレイテッド | 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体 |
| EP2144614A1 (en) | 2007-04-12 | 2010-01-20 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| EP2213655A1 (en) * | 2007-04-27 | 2010-08-04 | Paratek Pharmaceuticals, Inc. | Methods For Purifying Aminoalkyl Tetracycline Compounds |
| EA201070233A1 (ru) | 2007-07-06 | 2010-08-30 | Паратек Фармасьютикалс, Инк. | Способы синтеза замещённых соединений тетрациклина (варианты) |
| MX2010009693A (es) | 2008-03-05 | 2010-12-20 | Paratek Pharm Innc | Compuestos de monociclina y metodos de uso de la misma. |
| PT2271348T (pt) | 2008-03-28 | 2018-04-16 | Paratek Pharm Innc | Formulação de comprimido oral de composto de tetraciclina |
| EP2276342A4 (en) * | 2008-04-14 | 2012-02-22 | Paratek Pharm Innc | SUBSTITUTED TETRACYCLIN COMPOUNDS |
| TW202436282A (zh) | 2008-05-19 | 2024-09-16 | 美商Ｐｒｔｋ Ｓｐｖ２公司 | 四環素化合物之甲苯磺酸鹽及同素異形體 |
| US9629809B2 (en) | 2008-07-21 | 2017-04-25 | Si Group, Inc. | High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms |
| MX337488B (es) | 2008-07-21 | 2016-03-08 | Si Group Inc | Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes. |
| JP2012503017A (ja) * | 2008-09-19 | 2012-02-02 | パラテック ファーマシューティカルズ インコーポレイテッド | 関節リウマチの治療用のテトラサイクリン化合物および関連する治療方法 |
| DE202010018378U1 (de) | 2009-04-10 | 2016-04-07 | Tufts Medical Center, Inc. | PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1) |
| PL2707003T3 (pl) | 2011-05-12 | 2019-11-29 | Paratek Pharm Innc | Krystaliczne sole amidu kwasu (4s,4as,5ar,12as)-4-dimetyloamino-3,10,12,12a-tetrahydroksy-7-[(metoksy(metylo)amino)metylo]-1,11-diokso- 1,4,4a,5,5a,6,11,12a-oktahydronaftaceno- 2-karboksylowego i sposoby ich stosowania |
| US10383884B2 (en) | 2016-11-01 | 2019-08-20 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
| EP3654988B1 (en) | 2017-07-21 | 2023-09-06 | Almirall, LLC | Sarecycline for the treatment of non-inflammatory acne lesions |
-
1966
- 1966-05-31 NL NL6607516A patent/NL6607516A/xx unknown
- 1966-11-08 FR FR82837A patent/FR5953M/fr not_active Expired
-
1967
- 1967-05-16 GB GB22620/67A patent/GB1131007A/en not_active Expired
- 1967-05-18 IL IL28009A patent/IL28009A/en unknown
- 1967-05-18 SE SE06961/67A patent/SE354417B/xx unknown
- 1967-05-22 GR GR670133861A patent/GR33861B/el unknown
- 1967-05-24 ES ES340956A patent/ES340956A1/es not_active Expired
- 1967-05-25 SU SU1158241A patent/SU510986A3/ru active
- 1967-05-26 BE BE699091D patent/BE699091A/xx not_active IP Right Cessation
- 1967-05-26 US US641483A patent/US3557280A/en not_active Expired - Lifetime
- 1967-05-26 DE DE1617576A patent/DE1617576C3/de not_active Expired
- 1967-05-30 AT AT502267A patent/AT272522B/de active
- 1967-05-30 FI FI1517/67A patent/FI43622B/fi active
- 1967-05-30 DK DK282167AA patent/DK117587B/da unknown
- 1967-05-30 IT IT37118/67A patent/IT1140250B/it active
- 1967-05-30 NO NO00168375A patent/NO126298B/no unknown
- 1967-05-30 YU YU1086/67A patent/YU31326B/xx unknown
- 1967-05-31 JP JP42034292A patent/JPS5010373B1/ja active Pending
- 1967-05-31 CH CH766867A patent/CH490087A/de not_active IP Right Cessation
- 1967-05-31 LU LU53788A patent/LU53788A1/xx unknown
- 1967-05-31 CS CS3970A patent/CS151454B2/cs unknown
-
1971
- 1971-12-30 MY MY15/71A patent/MY7100015A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LU53788A1 (enExample) | 1967-07-31 |
| DE1617576B2 (de) | 1980-04-10 |
| DK117587B (da) | 1970-05-11 |
| CS151454B2 (enExample) | 1973-10-19 |
| MY7100015A (en) | 1971-12-31 |
| YU31326B (en) | 1973-04-30 |
| GR33861B (el) | 1968-02-09 |
| FI43622B (enExample) | 1971-02-01 |
| DE1617576A1 (de) | 1972-04-27 |
| NO126298B (enExample) | 1973-01-22 |
| ES340956A1 (es) | 1968-06-16 |
| BE699091A (enExample) | 1967-11-27 |
| GB1131007A (en) | 1968-10-16 |
| IT1140250B (it) | 1986-09-24 |
| IL28009A (en) | 1970-08-19 |
| SU510986A3 (ru) | 1976-04-15 |
| SE354417B (enExample) | 1973-03-12 |
| JPS5010373B1 (enExample) | 1975-04-21 |
| AT272522B (de) | 1969-07-10 |
| CH490087A (de) | 1970-05-15 |
| FR5953M (enExample) | 1968-04-16 |
| US3557280A (en) | 1971-01-19 |
| NL6607516A (enExample) | 1967-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1617576C3 (de) | Verfahren zur Herstellung eines Injektionspräparates auf Basis einer wäßrigen Lösung eines Oxytetracyclin-Magnesium-Komplexes | |
| EP0136470B1 (de) | Injizierbare Lösung zur Behandlung von Entzündungen | |
| WO2001078732A1 (de) | Lagerstabile infusionslösung des ciprofloxacins | |
| DE3119510C2 (enExample) | ||
| DE60101979T2 (de) | Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel | |
| DE3751589T2 (de) | Anthracyclin-Glucosid enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs. | |
| DE1467749A1 (de) | Verfahren zur Herstellung von stabilen Tetracyclinpraeparaten | |
| DE3700379C2 (enExample) | ||
| DE69232409T2 (de) | Ungepufferte, vorgemischte ranitidin-formulierung | |
| DE2546474A1 (de) | Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung | |
| DE69231098T2 (de) | Lyophilisierte zusammensetzung, die s(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis(2,6-piperazindion)enthält | |
| DE2723936A1 (de) | Ophthalmische loesung fuer die glaucom-behandlung | |
| DE1792448C3 (de) | Verfahren zur Herstellung von zur parenteralen Verabreichung geeigneten stabilen Lösungen von therapeutisch anwendbaren Benzodiazepinderivaten | |
| DE2754882A1 (de) | Pharmazeutische zusammensetzungen | |
| DE2820992A1 (de) | Arzneimittel auf nitroimidazol-basis | |
| AT241028B (de) | Verfahren zur Herstellung eines eisenhaltigen Präparats für intramuskuläre Injektion | |
| DE2538678A1 (de) | Injizierbare loesungen | |
| DE69000268T2 (de) | Stabilisiertes antitumormittel. | |
| DE1417343C (de) | Flüssige stabile Arzneimittel auf der Basis von Magnesiumkomplexsalzen des Oxytetracycline. Arun: Chas. Pfizer & Co Inc., Brooklyn, N.Y. (V.St.A.); Ttr: Beil, Dr. W.; Hoeppener, A.; Rechtsanwälte, 6230 Frankfurt-Höchst | |
| AT218175B (de) | Röntgenkontrastmittel zur Sichtbarmachung der Gallenwege | |
| DE3343818C2 (enExample) | ||
| DE1901915C3 (de) | Arzneimittel auf der Basis von a -Aminobenzylpenicillintrihydrat | |
| AT142713B (de) | Verfahren zur Herstellung von in Lösungen haltbaren Präparaten, die anaesthesierend wirkende und gefäßverengende Mittel enthalten. | |
| DE2026864C (de) | 2-Äthyl- oder 2-Propylthioisonikotinsäureamid enthaltende InjektionsJösungen | |
| AT261812B (de) | Verfahren zur Herstellung einer stabilen Lösung von 6-Desmethyl-tetracyclin oder 7-Chlor-6-desmethyl-tetracyclin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |